Latest News

Quanta Receives £1.85 Million i4i Award.

Seroba investee company, Quanta Fluid Solutions, Receives £1.85 Million i4i Award to Develop an Advanced Haemodialysis System for Nocturnal Use.

Alcester, Warwickshire, UK, 18 August 2015: Seroba investee company, Quanta Fluid Solutions Ltd (“Quanta” or the “Company”), a pioneering developer of...


Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment.

Dublin – April 15, 2015 – Seroba's investee company, Heart Metabolics Limited, a biotechnology company focused on the development of drugs for orphan diseases including hypertrophic cardiomyopathy (HCM), today announced that it has received an agreement letter from the U.S. Food and Drug Administration (FDA) related to the company’s proposed Phase 3 trial Special Protocol...


Veryan Secures £18m Series B Funding.

January 2015.  Veryan Medical has announced a £18m series B funding round led by Imperial alongside co-investors Invesco Asset Management, Seroba Life Sciences and Seven Mile. This investment will be utilised to commercialise the BioMimics 3D stent in international markets and to fund an IDE study in pursuit of FDA approval for the device. The objective of Veryan’s...


< back to home page